Investment Thesis
aTYR Pharma is a pre-revenue stage biotech company with minimal commercialization progress and severe financial deterioration. The company is burning cash at an unsustainable rate ($62M operating cash outflow) while generating only $190K in revenue, indicating clinical-stage operations with no meaningful product commercialization. At current burn rates, the company has limited runway and faces imminent capital requirements.
Strengths
- Strong liquidity position with 5.3x current ratio providing near-term operational flexibility
- Conservative leverage with 0.04x debt-to-equity ratio indicating low financial risk from debt obligations
- Modest stockholders' equity base of $67.5M provides some capital cushion for continued R&D investment
Risks
- Extreme cash burn of $62M annually with only $10.7M cash on hand, providing less than 2 months of runway at current burn rates
- Negligible revenue of $190K indicates no viable commercial products and complete dependence on capital markets for funding
- Massive net losses of $74.1M representing -39,009.5% net margin, demonstrating fundamental unprofitability and inability to achieve commercialization milestones
- Operating cash flow deficit of $62M annually with negative free cash flow margin of -32,664.7% indicates unsustainable business model
- High insider trading activity (6 Form 4 filings in 90 days) may signal management concern about company trajectory
Key Metrics to Watch
- Cash burn rate and cash runway remaining before next financing requirement
- Revenue growth trajectory and progress toward commercial viability
- R&D spending efficiency and clinical trial advancement status
- Quarterly cash position and liquidity levels
- Insider trading patterns and management confidence indicators
Financial Metrics
Revenue
190.0K
Net Income
-74.1M
EPS (Diluted)
$-0.80
Free Cash Flow
-62.1M
Total Assets
93.0M
Cash
10.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-40,856.3%
Net Margin
-39,009.5%
ROE
-109.8%
ROA
-79.7%
FCF Margin
-32,664.7%
Balance Sheet & Liquidity
Current Ratio
5.30x
Quick Ratio
5.30x
Debt/Equity
0.04x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
2.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T09:42:12.316922 |
Data as of: 2025-12-31 |
Powered by Claude AI